Amplia Therapeutics develops focal adhesion kinase (FAK) inhibitors for cancer and fibrosis, led by narmafotinib. Company news centers on clinical development of narmafotinib in fibrotic cancers, including pancreatic and ovarian cancer, where updates describe combination studies with standard-of-care chemotherapy, trial data presentations, safety and response analyses, and biomarker work.
Recurring announcements also cover preclinical research in KRAS-mutated cancer models, GMP manufacturing and drug-supply scale-up for narmafotinib, patent and regulatory communications, quarterly activities and cash-flow reporting, and the company’s ASX listing and OTCQB quotation under INNMF.
Amplia Therapeutics (OTCQB:INNMF) reported preclinical poster data on March 6, 2026 showing its FAK inhibitor narmafotinib enhances the activity of kRAS inhibitors across pancreatic, lung and ovarian cancer models. The data suggest narmafotinib can block resistance pathways and may improve efficacy and durability of kRAS therapies.
The findings were presented at the AACR Special Conference: RAS Oncogenesis and Therapeutics; a copy of the poster is available from the company.
Amplia Therapeutics (OTCQB:INNMF) opened two US sites for the AMPLICITY pancreatic cancer trial: University of California, Irvine and The Cleveland Clinic.
These join two Australian sites (Epworth Hospital and Genesis Care). Three more US sites are expected to open in the coming weeks as recruitment continues for narmafotinib plus FOLFIRINOX.
Amplia Therapeutics (OTCQB: INNMF; ASX: ATX) reported clinical and financial progress for the quarter ending 31 December 2025, highlighting a 35% confirmed objective response rate (19/55) in the ACCENT trial and initiation of the Phase 1b/2a AMPLICITY trial combining narmafotinib with FOLFIRINOX.
Other highlights: positive FDA feedback on dose optimisation, a US patent extending protection to at least 2040, successful OTCQB uplisting, advancement of a Next & Bio preclinical collaboration, and a closing cash position of $31.5 million.
Amplia Therapeutics (OTCQB:INNMF) announced successful completion of a large-scale manufacture campaign of narmafotinib, producing approximately 13 kg of API to required purity and quality on Jan 22, 2026. The campaign moved production from an R&D facility to a commercial GMP environment, delivering reported production efficiencies and cost savings.
The ~13 kg API will be converted into oral capsules to supply Amplia’s pancreatic cancer trials and other planned studies, supporting Phase‑3 readiness and the company’s clinical development pipeline.
Amplia Therapeutics (ASX:ATX; OTCQB:INNMF) presented interim Phase 2a ACCENT trial data in metastatic pancreatic cancer at the ASCO Gastrointestinal Cancer Symposium on Jan 9, 2026, announced Jan 12, 2026. The poster reported updated progression-free survival (PFS) of 7.7 months versus 5.5 months for gemcitabine plus Abraxane alone, and an overall response rate (ORR) of 35% (rising to 42% including unconfirmed responses). Narmafotinib, a FAK inhibitor given with standard chemotherapy, was described as well tolerated with an adverse effect profile similar to chemotherapy alone. A copy of the poster is available on the company website.
Amplia Therapeutics (OTCQB:INNMF) announced that its CMO, Dr Jason Lickliter, will present a poster at the ASCO Gastrointestinal Cancers Symposium in San Francisco, January 8-10, 2026.
The poster, titled "Narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel as first-line treatment for patients with metastatic pancreatic cancer (ACCENT trial): Phase 2a results", will present updated data from the ongoing ACCENT trial. The full abstract will be published at 5:00 PM US ET on January 5, 2026.
Poster details: Friday, January 9, 2026, 11:30 AM–1:00 PM US PT, Level 1 West Hall Moscone West, Poster K5.
Amplia Therapeutics (OTCQB:INNMF / ASX:ATX) entered a second-phase preclinical collaboration with Korean drug‑screening company Next & Bio on Dec 19, 2025 to test combination therapy of Amplia’s FAK inhibitor narmafotinib with experimental kRAS inhibitors.
The work uses patient‑derived pancreatic cancer cell models that replicate the tumour environment; initial tests showed promising narmafotinib activity and will be presented at an upcoming scientific conference. The new phase will evaluate potential synergy between FAK and kRAS inhibition and is positioned to support future partnering and commercial opportunities.
Amplia Therapeutics (OTCQB:INNMF) reported an additional confirmed partial response in the ongoing ACCENT trial for metastatic pancreatic cancer, bringing the confirmed objective response rate to 35% (19/55).
The ACCENT trial tests narmafotinib combined with gemcitabine and nab-paclitaxel; the 35% ORR is presented alongside a historical benchmark ORR of 23% from the MPACT trial for gemcitabine and nab-paclitaxel alone. Updated ACCENT data were presented by CEO Dr Chris Burns at the Life Sciences Virtual Investor Forum on December 11 (US ET) / December 12 (AEDT), and the ASX announcement was authorised by the CEO.
Amplia Therapeutics (OTCQB:INNMF) received a Certificate of Grant from the US Patent and Trademark Office for a patent titled A salt and crystal form of a FAK inhibitor, extending protection for the company's clinically developed FAK inhibitor narmafotinib to at least 2040 in the US and other jurisdictions. The grant follows a September 2025 notification of allowance and complements existing patents already granted in Europe, Japan, India, Korea and Australia. The patent specifically protects the particular salt/crystal form of narmafotinib being developed clinically. The company stated protection in additional regions is under review by respective patent offices and said the grants strengthen narmafotinib's long-term intellectual property position.